Dr. Yin is Chief Technology Officer, and General Manager in China at D2M. As the CTO, he has over 15 years of experience in CMC and IND enabling study & development. In the past, he has successfully delivered multiple IND applications and PD technology transfers, including establishment of the first 10,000 L antibody stainless-steel tank production in China.
Prior to joining D2M, he served as Deputy General Manager at Hengrui-Suzhou Suncadia Biopharmaceuticals, overseeing early- stage process development and late-stage tech transfer and scale-up. Before Hengrui, Dr. Yin held a progressive role in CMC, process development, and analytical science at several biopharma companies including Genetech/Wuxi Biologics/BI (China) and I-mab.
Dr. Yin holds a Ph.D. in Biochemistry and Molecular Biology and a B.S. in Biochemistry from UCLA.